# Efficacy of Nab-PHP Versus TCbHP in Neoadjuvant Therapy for HER2-positive Early Breast Cancer

> **NCT07057427** · PHASE3 · RECRUITING · sponsor: **Henan Cancer Hospital** · enrollment: 812 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Nab paclitaxel
- **DRUG:** Docetaxel and Carboplatin
- **DRUG:** Trastuzumab + Pertuzumab

## Key facts

- **NCT ID:** NCT07057427
- **Lead sponsor:** Henan Cancer Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06-24
- **Primary completion:** 2028-06-30
- **Final completion:** 2029-06-30
- **Target enrollment:** 812 (ESTIMATED)
- **Last updated:** 2025-07-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07057427

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07057427, "Efficacy of Nab-PHP Versus TCbHP in Neoadjuvant Therapy for HER2-positive Early Breast Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT07057427. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*